GUARDANT
Hereditary Cancer

Now available from Guardant Health: **Germline testing.**

Identify guideline-recommended genetic variants associated with hereditary cancer risk across 12+ tumor types.

82-gene
hereditary cancer panel

AIP, ALK, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CHEK2, CTNNA1, DICER1, EGFR, EPCAM, FANCA, FH, FLCN, GALNT12, GREM1, HOXB13, KIT, LZTR1, MAX, MBD4, MC1R, MEN1, MET, MITF, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51C, RAD51D, RB1, RET, RHBDF2, RNF43, RPS20, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TERT, TMEM127, TP53, TSC1, TSC2, VHL, WT1, XPA, XPC

Get germline results as a standalone or add-on to *all* Guardant tests.*

Germline sample requirements:

Standalone or add-on to tissue

2 tubes of blood

Order with Guardant360 Tissue or on its own.†

Add-on to liquid

No additional sample required

Order with Guardant360 CDx, Guardant360 Liquid, Guardant360 Response, or Guardant Reveal.‡

Convenient ordering

Easily order or add germline testing via the paper order form, online portal, or EMR.*

2-3 weeks turnaround time§

EMR, electronic medical record.

* Add-on available to all Guardant oncology tests. Germline results are issued as a separate clinical report for both standalone and add-on testing.

† Germline test orders that are standalone or added on to a Guardant360 Tissue test can be submitted using the paper form and a Guardant blood collection kit.

‡ At launch of Guardant Hereditary Cancer, add-on orders with Guardant Reveal will require completion of both the Guardant Reveal and Guardant Health order forms. Samples must be submitted using the Guardant Reveal blood collection kit and a second Guardant blood collection kit.

§ Median turnaround time from sample receipt to results.

Important note: Guardant360 Tissue, Guardant360 Liquid, Guardant360 Response, and Guardant Reveal were developed as a Laboratory Developed Tests (LDTs), and their performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. These tests have not been cleared or approved by the US FDA. Guardant Hereditary Cancer was developed as a Laboratory Developed Test (LDT) and has not been cleared or approved by the US FDA.

GUARDANT™